Kiora Pharmaceuticals, Inc.
KPRXNASDAQHealthcareBiotechnology
Regular session
$2.67
+$0.01 · +0.38%
KPRX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
33
Expensive
Momentum
44
Neutral
Sentiment
47
Mixed
Risk resilience
54
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteKiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Brian Strem
- Listed since
- Feb 13, 2015
- Employees
- 13
Market position
Day range
Current $2.67
52-week range
Current $2.67
- Open
- $2.65
- Previous close
- $2.66
- Volume
- 2.13K
- 0.06× average
- Average volume
- 33.03K
- Average daily volume
- Market cap
- 11.83M USD
- Beta
- -0.39
- Market reference 1
- 50-day average
- $2.5653
- +4.08% above average
- 200-day average
- $2.3118
- +15.50% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -243.68K USD
- P/E (TTM)
- -1.07×
- P/B (TTM)
- 0.98×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.02×
- Earnings yield
- -134.02%
- Free cash flow yield
- -124.58%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -67.19%
- Return on assets
- -44.67%
- Return on invested capital
- -40.69%
Financial health
- Debt / equity
- 0.02×
- Current ratio
- 5.99×
- Altman Z-score
- -9.07
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 16M USD | — | — | — |
| Cost of goods sold | 24.8K USD | — | — | — | — |
| Gross profit | −24.8K USD | 16M USD | — | — | — |
| Research and development | 10.78M USD | 4.9M USD | 4.03M USD | 3.45M USD | 5.35M USD |
| Selling, general, and administrative | 5.75M USD | 5.54M USD | 4.66M USD | 8.28M USD | 5.32M USD |
| Operating expenses | 9.43M USD | 11.49M USD | 12.59M USD | 12.31M USD | 14.24M USD |
| Interest income | 894K USD | 1.25M USD | 173.99K USD | 56.89K USD | 1.14K USD |
| Interest expense | 19.96K USD | 21.45K USD | 11.13K USD | 8.6K USD | 6.85K USD |
| Depreciation and amortization | 24.8K USD | 19.21K USD | 51.8K USD | 41.61K USD | 45.3K USD |
| Operating income | −9.46M USD | 4.51M USD | −12.59M USD | −12.31M USD | −14.24M USD |
| Net income | −10.84M USD | 3.59M USD | −12.51M USD | −13.58M USD | −13.77M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 64%
- 7 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -1.00%
- 11 comparable reports
- Latest EPS result
- -0.34
- Estimate -0.47 · Beat by 27.66%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
KPRX peers
Continue in GoAI
Research KPRXresearch.disclaimer